Features of Ivim Health GLP-1 Ivim Health packages its GLP-1 program with several features beyond the injection itself: Individualized dosing model: Weekly check-ins let your provider adjust your dose in response to your symptoms and progress, instead of a fixed monthly escalation
Novo Nordisks semaglutide, the GLP-1 analog used in Ozempic and Wegovy, showed an average weight loss of 10.6% at 68 weeks with the 2.4 mg dose in adults with type 2 diabetes and obesity or overweight in the STEP 2 Phase 3 trial
The factors behind obesity-induced hypertension are numerous, and often, they are effective concurrently
JACC 82(9):833955 Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR et al (2020) Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
The GLP-1 medication Ozempic is now available in pill form for people with type 2 diabetes
Retatrutide is a triple-action peptide that acts as an agonist at GLP-1, GIP, and glucagon receptors compared to other peptides
